Literature DB >> 8153879

A drug that facilitates glutamatergic transmission reduces exploratory activity and improves performance in a learning-dependent task.

R Granger1, U Staubli, M Davis, Y Perez, L Nilsson, G A Rogers, G Lynch.   

Abstract

A recently developed benzamide compound which facilitates glutamate receptor-mediated synaptic responses was used to test behavioral consequences of enhanced glutamatergic transmission. The drug was found to depress exploratory activity by rats in a novel environment. At a dose below threshold for causing such effects, drug-treated and control rats exhibited no evident behavioral differences during the acquisition phase of a radial maze experiment. Yet, when tested 2.5 h later, experimental animals were more likely than controls to choose maze arms that had not been entered during the acquisition session, suggesting that the drug enhanced retention of information about prior choices and the maze environment.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8153879     DOI: 10.1002/syn.890150409

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  23 in total

1.  Combinatorial chemistry and high-throughput screening in drug discovery: different strategies and formats.

Authors:  P Seneci; S Miertus
Journal:  Mol Divers       Date:  2000       Impact factor: 2.943

2.  AMPA receptor facilitation accelerates fear learning without altering the level of conditioned fear acquired.

Authors:  M T Rogan; U V Stäubli; J E LeDoux
Journal:  J Neurosci       Date:  1997-08-01       Impact factor: 6.167

3.  S 18986 reverses spatial working memory impairments in aged mice: comparison with memantine.

Authors:  Matthias Vandesquille; Ali Krazem; Caroline Louis; Pierre Lestage; Daniel Béracochéa
Journal:  Psychopharmacology (Berl)       Date:  2011-01-28       Impact factor: 4.530

Review 4.  Therapeutic potential of positive AMPA receptor modulators in the treatment of neuropsychiatric disorders.

Authors:  Stefano Marenco; Daniel R Weinberger
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

5.  Evaluation of the pro-cognitive effects of the AMPA receptor positive modulator, 5-(1-piperidinylcarbonyl)-2,1,3-benzoxadiazole (CX691), in the rat.

Authors:  M L Woolley; K A Waters; J E Gartlon; L P Lacroix; C Jennings; F Shaughnessy; A Ong; D J Pemberton; M H Harries; E Southam; D N C Jones; L A Dawson
Journal:  Psychopharmacology (Berl)       Date:  2008-09-16       Impact factor: 4.530

6.  Glutamate receptor-mediated restoration of experience-dependent place field expansion plasticity in aged rats.

Authors:  Sara N Burke; Andrew P Maurer; Zhiyong Yang; Zaneta Navratilova; Carol A Barnes
Journal:  Behav Neurosci       Date:  2008-06       Impact factor: 1.912

Review 7.  Activation of mammalian target of rapamycin and synaptogenesis: role in the actions of rapid-acting antidepressants.

Authors:  Jason M Dwyer; Ronald S Duman
Journal:  Biol Psychiatry       Date:  2013-01-04       Impact factor: 13.382

8.  A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.

Authors:  Donald C Goff; J Steven Lamberti; Andrew C Leon; Michael F Green; Alexander L Miller; Jayendra Patel; Theo Manschreck; Oliver Freudenreich; Steven A Johnson
Journal:  Neuropsychopharmacology       Date:  2007-05-09       Impact factor: 7.853

9.  Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia--sub-chronic and early postnatal PCP treatment in attentional set-shifting.

Authors:  Brian Villumsen Broberg; Birte Yding Glenthøj; Rebecca Dias; Dorrit Bjerg Larsen; Christina Kurre Olsen
Journal:  Psychopharmacology (Berl)       Date:  2009-04-24       Impact factor: 4.530

10.  Role of mental retardation-associated dystrophin-gene product Dp71 in excitatory synapse organization, synaptic plasticity and behavioral functions.

Authors:  Fatma Daoud; Aurora Candelario-Martínez; Jean-Marie Billard; Avi Avital; Malik Khelfaoui; Yael Rozenvald; Maryvonne Guegan; Dominique Mornet; Danielle Jaillard; Uri Nudel; Jamel Chelly; Dalila Martínez-Rojas; Serge Laroche; David Yaffe; Cyrille Vaillend
Journal:  PLoS One       Date:  2008-08-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.